Metavia INC. (MTVA) — 10-K Filings
All 10-K filings from Metavia INC.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
MetaVia Pushes MASH, Obesity Drugs Amidst Mounting Losses
— Mar 26, 2026 Risk: high
MetaVia Inc. (MTVA) reported continued net losses for the fiscal year ended December 31, 2025, as it remains a clinical-stage biotechnology company without reve -
MetaVia Inc. Files 2024 10-K, Details Financials
— Mar 20, 2025 Risk: medium
MetaVia Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting on its operations as a pharmaceutical preparations company. The filing detai -
NeuroBo Pharmaceuticals, Inc. Files 2023 Annual Report (10-K)
— Mar 28, 2024 Risk: medium
NeuroBo Pharmaceuticals, Inc. (MTVA) filed a Annual Report (10-K) with the SEC on March 28, 2024. NeuroBo Pharmaceuticals, Inc. filed its 2023 10-K report on Ma
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX